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OBJECTIVE: The purpose of the study was to assess cost-
effectiveness of novel DMARDs for RA therapy from the
managed care perspective. METHODS: Utilizing a claims
database, RA patients initiated on various dose regimens
of leﬂunomide (LEF), etanercept (ETA) and inﬂiximab
(INF) in 1999 or 2000 were followed for 12 months post
drug index date and mean RA-related direct medical
charges were calculated for each study cohort. Twelve-
month estimates of the American College of Rheumatol-
ogy response criteria (ACR 20) and mean change in the
Health Assessment Questionnaire Disability Index (HAQ
DI) were used as effectiveness measures from published
clinical trials. Average (CE) and incremental cost-
effectiveness (ICER) ratios were calculated and one-way
sensitivity analyses were performed. RESULTS: Mean
RA-related direct medical charges (95% CI) for LEF, ETA
and INF for 1-year of therapy post-index date were
$16,107 (14654, 17856), $25,550 (24251, 26711) and
$55,195 (49928, 60305). Twelve-month ACR 20 esti-
mates were 52%, 72% and 42% and mean changes in
HAQ DI were -0.45, -0.62 and -0.29, respectively. The
LEF CE [ACR 20] was $30,976 compared to $35,486
(ETA) and $131,417 (INF) while LEF CE [HAQ DI] 
was $35,794 compared to $41,210 (ETA) and $190,329
(INF). Sensitivity analyses of key parameters: cost,
ACR20, HAQDI did not inﬂuence the rank order of
results. Worst-case estimates for LEF [ACR 20 = 0.51;
HAQ DI = -0.41] resulted in a CE of $31,583 and
$39,286, which was lower than the base-case CE of ETA
and INF. The ICER for ETA vs. LEF was $47,213 [ACR
20] and $55,544 [HAQ DI]. Both LEF and ETA domi-
nated INF. CONCLUSION: Evidence from the economic
analysis demonstrates that LEF is a cost-effective alter-
native among novel DMARDs for RA patients in a
managed care setting.
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OBJECTIVES: Rheumatoid arthritis (RA) affects 1% of
adults in the developed world, impacting on functional
activities and life expectancy. The burden of RA is sig-
niﬁcant, with substantial direct medical costs and indirect
costs, such as time off work and exclusion from the work-
force. Treatments include medication, functional rehabil-
itation and surgery. The objective was to assess the
hospital resource use and costs for treating RA in France,
from a health insurance perspective. METHODS: Using
the national hospital activity database, PMSI, patients
with either a primary, secondary or related RA diagnosis
were identiﬁed and their hospital care analysed. PMSI
data covers almost all public and private hospitals in
France, providing Health Authorities with activity 
indicators for budget allocations. RA admissions were
selected by ICD-10 codes M05 and M06 and analysed by
primary, secondary and related RA diagnoses. Hospital
activity captured included procedures undertaken and
occupied bed days, and was separated into public and
private hospital activity. Comorbidities and DRGs 
represented were also identiﬁed. RESULTS: In 2000,
51,985 admissions were related to RA. Public hospitals
accounted for 75% of admissions; 74% were women.
Procedures were performed in 70% of admissions, with
an average of 3.6 per admission. Of these, 3,118 were
RA-related joint procedures. The mean length of stay was
6.4 days +/-10.1, corresponding to 329,098 occupied 
bed days. Twenty-four percent of bed days were due to
primary RA and 71% to secondary RA. Main DRGs were
341 and 340 (connective tissue diseases), 808 (diseases of
the musculoskeletal system and connective tissue, ambu-
latory treated) and 295 (major intervention on joint
replacement), which accounted for 83% of primary RA
admissions and cost €31 million (80% of primary RA
cost). CONCLUSIONS: The burden of RA is signiﬁcant
in the French healthcare system, with high hospital
resource use, including costly joint replacement 
procedures.
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OBJECTIVES: The primary objective of this study is to
estimate the number of hip/knee replacements performed
in the nation as well as to produce synthetically derived
estimates for Ohio. These estimates were then used for
the estimation of the economic burden associated with
these arthritis related surgeries. METHODS: The 2000
National Hospital Discharge Survey (NHDS) was utilized
to estimate the number of hip/knee replacements per-
formed in the nation. The ICD-9-CM procedure codes
used to identify patients are ICD-9-CM 81.51 (total hip
replacement) and 81.54 (Total/partial knee replacement).
The NHDS recorded up to four ICD-9-CM procedures
for each discharge. Since the main purpose of this study
was to estimate the burden of arthritis-related surgeries,
all four procedures recorded for each patient were con-
sidered for the identiﬁcation of arthritis-related surgery.
Then, the total number of hip/knee replacements in Ohio
was estimated by applying age and sex distributions based
on the U.S. census 2000. Since the NHDS does not
include cost information on hospital discharges, diagno-
sis related group (DRG) reimbursement was used to
approximate the total hospital charges. RESULTS: In the
United States, approximately 9.6 billion dollars were used
for 439,833 hip and knee replacement surgeries in the
year 2000. In Ohio, approximately 407 million dollars
were spent for 18,731 hip and knee replacement surg-
eries. CONCLUSIONS: The estimated cost for joint
replacements alone was nearly $10 billion in the United
States during the year 2000. The total cost of joint
replacements will be much higher if we include pre and
post-operation care.
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OBJECTIVES: Rheumatoid arthritis (RA) is an important
cause of admission to UK hospital wards, although few
estimates of the cost implications of RA in the hospital
sector exist in the literature. This study presents a method
of estimating the hospital burden of RA in England.
METHODS: The CHKS hospital dataset contains aggre-
gated, anonymised information on diagnosis, hospital
experience, and patient demographics for over 80 million
episodes in the UK. The CHKS sample, which covers
approximately 55% of UK hospital admissions, was used
to describe and assess the impact of RA-related episodes
in England. Patients with RA (ICD-10 codes M05, M06)
as a primary or secondary diagnosis were analysed 
for comorbidities, procedures (identiﬁed using OPCS-4
codes), length of stay, and for repeat admissions during
the year. RESULTS: We identiﬁed 10,425 unique patients
admitted with primary RA in 2001. These patients had a
total of 17,395 separate episodes, 42% of which were day
cases. Mean inpatient length of stay was 6.9 days, result-
ing in 70,305 occupied bed days. At least 1 invasive pro-
cedure was undertaken in 74% of episodes. While these
were mainly injections and infusions, there were 1650
joint replacements. From a resource use perspective, the
10% of procedures involving joint replacement accounted
for 22% of total occupied bed days. Forty four percent
of patients with a primary RA episode also had primary
RA episodes in the previous 4 years. A further 15,640
unique patients with secondary RA were also identiﬁed,
having a total of 28,979 episodes. CONCLUSIONS:
Each year, there are over 25,000 unique patients with a
RA related episode in England. This represents a sub-
stantial resource burden in the National Health Service
(NHS). An effective and well-tolerated agent, such as an
anti-TNF therapeutic, would help reduce the burden on
an already overstretched healthcare sector.
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OBJECTIVES: A local clinical trial showed that celecoxib
therapy was comparable in efﬁcacy to diclofenac plus
omeprazole in preventing recurrent gastrointestinal bleed-
ing in high-risk patients. The objective of the present
study is to evaluate the economic impact of celecoxib
therapy versus diclofenac plus omeprazole for the treat-
ment of arthritic patients with high risks. METHODS:
A decision tree was designed to analyze the economic 
and clinical outcomes of a randomized controlled clinical
trial. Two hundred and eighty-seven patients with arthri-
tis and active ulcer bleeding were recruited. After ulcer
healing had been conﬁrmed, the patients were random-
ized to receive either celecoxib 200mg twice daily or
diclofenac twice daily plus 20mg of omeprazole daily for
6 months. The clinical outcome was incidence of ulcer
bleeding. The healthcare resource consumption associ-
ated with study patients was retrieved from the trial case
reports. The direct medical costs were estimated based
upon symptom-driven healthcare resources utilization.
The study was performed from the perspective of a public
health organization in Hong Kong. RESULTS: Seven out
of 144 patients (4.9%) in the celecoxib group and 9 
out of 143 patients (6.3%) in the diclofenac group 
experienced ulcer bleeding. The mean cost for manage-
ment of ulcer bleeding was HKD19,434 (95% CI:
HKD10,950–27,918) (1US = 7.8HKD). The mean total
cost of routine follow-up and differential diagnosis
during study period for patients in the celecoxib 
